

## ASCO 2026 Presentation Schedule - Boehringer Ingelheim

Abstract Title	Presenter	ASCO Session
<b>Zongertinib and HER2</b>		
PRO results from the Beamion LUNG-1 trial in treatment-naïve patients with HER2-mutant advanced NSCLC	Sabari, J. K.	Poster Presentation 406 — May 31, 9:00 AM – 12:00 PM CDT
Zongertinib in HER2-altered colorectal cancer: a pooled analysis from two clinical trials	Arnold, D.	Poster Presentation 292 — May 30, 9:00 AM – 12:00 PM CDT
Zongertinib combined with T-DXd in HER2-positive metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC): first results from a Phase Ib/II dose-escalation trial	Nakayama, I.	Poster Presentation 243 — May 30, 1:30 PM – 4:30 PM CDT
Beamion BCGC-1: Four new phase Ib/II cohorts to evaluate oral zongertinib with other agents in HER2-positive metastatic breast cancer (mBC) and metastatic colorectal cancer (mCRC)	Shitara, K.	Poster Presentation 303a — May 30, 1:30 PM – 4:30 PM CDT
Zongertinib combination therapy in HER2-positive metastatic breast cancer (mBC): first results from a phase Ib/II trial	Kitano, S.	Poster Presentation 158 — June 1, 1:30 PM – 4:30 PM CDT
Overall Survival by Genomic Profile in HER2-Positive (HER2+) Metastatic Breast Cancer: A Large US Clinico-Genomic Database Study	Tarantino, P.	Poster Presentation 159 — June 1, 1:30 PM – 4:30 PM CDT
Beamion LUNG3: Zongertinib in resectable HER2-mutant NSCLC	Cummings, A.	Poster Presentation 600a — May 31, 9:00 AM – 12:00 PM CDT
Zongertinib in previously treated advanced HER2-mutant non-small cell lung cancer: A single-center study	Kong, J.	Publication Only: Lung Cancer—Non-Small Cell Metastatic
<b>Obixtamig and DLL3</b>		
DAREON®-8: updated efficacy and safety from a phase I dose-escalation/expansion trial of first-line obixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC)	Peters, S.	Poster Presentation 563 — May 31, 9:00 AM – 12:00 PM CDT
Analysis of delta-like ligand 3 (DLL3) expression levels and characteristics of patients with advanced extrapulmonary neuroendocrine carcinomas (epNECs) from an ongoing phase I trial	Gambardella, V.	Poster Presentation 432 — May 30, 1:30 PM – 4:30 PM CDT
Real-world patient characteristics, treatment patterns and clinical outcomes in patients diagnosed with extra-pulmonary neuroendocrine carcinoma (epNEC): A non-interventional multimodal database analysis in the US	Vijayvergia, N.	Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary